10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Azitra, a privately-held dermatology and microbiome specialist, has been awarded Rare Pediatric Disease designation for its candidate ATR-12, for the treatment of Netherton syndrome (NS). 28 May 2020
The US Food and Drug Administration has approved VESIcare LS (solifenacin succinate) oral suspension for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged two years and older. 28 May 2020
In a surprise market reaction following the announcement of a lucrative collaboration agreement today, US oncology-focussed biotech Arcus Biosciences saw its shares fall nearly 13% to $29.20 by late morning. 27 May 2020
US pharma major Bristol Myers Squibb has announced that the European Commission (EC) has approved Zeposia (ozanimod) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features. 27 May 2020
New research commissioned by the European Medicines Agency (EMA) will seek to ensure that the region is ready for effective monitoring of potential COVID-19 vaccines, once they are approved and in use. 27 May 2020
Swiss pharma giant Roche has announced positive top-line results from the Phase III Archway study, evaluating Port Delivery System with ranibizumab (PDS) in people living with neovascular or wet age-related macular degeneration (nAMD). 27 May 2020
Belgo-Dutch clinical-stage biotech argenx saw its shares close up nearly 30% at $190.00 on Tuesday, after it released top-line trial results for its myasthenia gravis drug candidate. 27 May 2020
US pharma major Merck & Co has not previously been the noisiest of drug companies when talking about its work in COVID-19, but it now appears to be making up for this. 27 May 2020
The US Food and Drug Administration has approved a label extension for Dupixent (dupilumab), to include treatment of children aged six to 11 with moderate-to-severe atopic dermatitis (AD). 27 May 2020
Privately-owned Austrian biotech Themis Bioscience and MSD (the trading name used by US pharma giant Merck & Co outside North America) have entered into a definitive agreement under which MSD will acquire Themis. 26 May 2020
Genomic analysis company ArcherDx has announced a strategic collaboration with AstraZeneca to develop assays to support multiple planned Phase III trials for the pharma major’s targeted immuno-oncology therapeutics. 26 May 2020
US biotech Novavax saw its share price jump by 14% in Tuesday morning’s trading as it became the latest company to announce that trials of its coronavirus vaccine have begun. 26 May 2020
Japanese drugmaker Shionogi said today that, at a meeting of the board of directors held on May 25, it was resolved to take up an option to acquire all the shares of US biotech firm Tetra Therapeutics. 26 May 2020
Less than two year after engaging a new head of the company, Stockholm, Sweden-based biotech Medivir has appointed a new chief executive, namely Yilmaz Mahshid. 26 May 2020
Canada-based BetterLife Pharma yesterday announced that it has secured "hard" lock-up agreements from shareholders of Altum Pharmaceuticals representing 67.12% of the outstanding common shares of the Canadian biotech. 26 May 2020
Study results released on Friday of 108 adults has found that Chinese biotech firm CanSino Biologic’s vaccine Ad5-nCoV produced neutralizing antibodies and T-cell response against SARS-CoV-2, but further research is needed to confirm whether the vaccine protects against SARS-COV-2 infection. 25 May 2020
Sino-America immuno-oncology biotech firm BeiGene has entered into an exclusive distribution agreement with Israel’s Medison Pharma to commercialize its BTK inhibitor Brukinsa (zanubrutinib) in Israel and the acceptance of a new drug application (NDA) in Israel for Brukinsa for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. 25 May 2020
The US Food and Drug Administration has approved Alunbrig (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. 23 May 2020
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Cambridge, USA-based City Therapeutics has announced its launch with a vision to lead the future of RNA interference (RNAi)-based medicine. 9 October 2024
Zephyrm Bioscience, a Cayman Islands-based biotech, has filed for an initial public offering (IPO) in Hong Kong, seeking to raise additional capital to advance its cell therapy pipeline. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024